TCGA-85-8479-01A-11R-2326-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 66
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.370
- G2M_CHECKPOINT+0.320
- KRAS_SIGNALING_DN+0.240
- P53_PATHWAY+0.220
- WNT_BETA_CATENIN_SIGNALING+0.180
- HEDGEHOG_SIGNALING+0.170
- MYC_TARGETS_V1+0.160
- MYOGENESIS+0.140
- PANCREAS_BETA_CELLS+0.130
- APICAL_JUNCTION+0.100
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.560
- INTERFERON_GAMMA_RESPONSE-0.530
- ALLOGRAFT_REJECTION-0.500
- IL6_JAK_STAT3_SIGNALING-0.420
- KRAS_SIGNALING_UP-0.370
- COMPLEMENT-0.360
- INFLAMMATORY_RESPONSE-0.330
- UV_RESPONSE_DN-0.310
- PROTEIN_SECRETION-0.300
- IL2_STAT5_SIGNALING-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-NC-A5HF-01A-11R-A26W-07 | — | cohortSQ1 | 0.860 |
| 2 | SRR11296886 | — | — | 0.815 |
| 3 | BS_P39SQPTS | Embryonal tumors | — | 0.815 |
| 4 | TCGA-85-A4QQ-01A-41R-A262-07 | — | cohortSQ1 | 0.814 |
| 5 | SRR8518143 | — | E | 0.805 |
| 6 | X299bbf8b.babb.4be2.a190.5411dc005aae | — | cohortA1 | 0.801 |
| 7 | dd75267f-824e-4ddc-9056-cdf0f500d39b | — | — | 0.797 |
| 8 | TCGA-P3-A6SX-01A-11R-A34R-07 | — | — | 0.796 |
| 9 | TCGA-56-A4BX-01A-11R-A24H-07 | — | cohortSQ2 | 0.792 |
| 10 | SRR27320660 | — | — | 0.790 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.320 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.240 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.220 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.180 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.170 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.160 | Inavolisib | — uncovered |
| MYOGENESIS | 0.140 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.130 | Cobimetinib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.090 | Temsirolimus | — uncovered |
| MYC_TARGETS_V2 | 0.090 | Idelalisib | — uncovered |
| HYPOXIA | 0.080 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.070 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.060 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.040 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.040 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.030 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.020 | Inavolisib | — uncovered |